288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Miles, D.W., Ciruelos, E.M., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Campone, M., Bondarenko, I., Nowecki, Z., Errihani, H., Paluch-Shimon, S., Wardley, A.M., Merot, J.L., du Toit, Y., Klingbiel, D., Revelant, V., Bachelot, T.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study
O'Shaughnessy, J., Sousa, S.P., Jurado, J. Cruz, Fallowfield, L.J., Auvinen, P., Pulido, C., Cvetanovic, A.S., Wilks, S.T., Ribeiro, L.A., Burotto, M., Boulet, T., Revelant, V., Theron, N., Trask, P., Wahyudi, L.A., Machackova, Z., Stamatovic, L.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article